Wilms Tumor 1 (WT1) Peptide Vaccine - Revision history

Lazy at 08:28, 18 January 2025

2025-01-18T08:28:40Z

← Older revision		Revision as of 01:28, 18 January 2025
Line 20:		Line 20:
	For more detailed information on the clinical trials and results, refer to the links provided.		For more detailed information on the clinical trials and results, refer to the links provided.
	\|links=https://pubmed.ncbi.nlm.nih.gov/30500939/, https://www.cancertherapyadvisor.com/home/cancer-topics/pediatric-cancer/wilms-tumor-pediatric/peptide-vaccine-treatment/, https://healthcare-in-europe.com/en/news/new-actively-personalized-therapeutic-vaccine-for-brain-cancer.html		\|links=https://pubmed.ncbi.nlm.nih.gov/30500939/, https://www.cancertherapyadvisor.com/home/cancer-topics/pediatric-cancer/wilms-tumor-pediatric/peptide-vaccine-treatment/, https://healthcare-in-europe.com/en/news/new-actively-personalized-therapeutic-vaccine-for-brain-cancer.html
	}}		\|overview=The Wilms Tumor Peptide Vaccine is an investigational immunotherapy currently available at the University Hospital of Heidelberg, Germany, targeting Wilms tumor, glioblastoma, and other cancers expressing the WT1 antigen. Although not FDA-approved, early clinical trials have demonstrated significant improvements in overall and disease-free survival, with common mild side effects such as injection site reactions and fatigue.}}

Lazy at 13:46, 25 December 2024

2024-12-25T13:46:41Z

← Older revision		Revision as of 06:46, 25 December 2024
Line 9:		Line 9:
	\|PFS_without=Varies depending on stage and treatment		\|PFS_without=Varies depending on stage and treatment
	\|PFS_with=Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005		\|PFS_with=Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005
			\|treatment_category=Vaccines
	\|usefulness_rating=4		\|usefulness_rating=4
	\|usefulness_explanation=Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers		\|usefulness_explanation=Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers

Lazy at 04:12, 14 June 2024

2024-06-14T04:12:24Z

← Older revision		Revision as of 21:12, 13 June 2024
Line 13:		Line 13:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Generally well-tolerated with few serious adverse events; typical side effects are mild		\|toxicity_explanation=Generally well-tolerated with few serious adverse events; typical side effects are mild
	\|~~book_text~~=Wilms tumor peptide vaccines represent an emerging treatment modality in the field of oncology. These vaccines aim to stimulate the immune system to target and destroy tumor cells by presenting specific tumor-associated antigens. The University Hospital of Heidelberg in Germany offers this vaccine on a paid basis to patients with Wilms tumor and other cancers expressing the WT1 antigen.		\|notes=Wilms tumor peptide vaccines represent an emerging treatment modality in the field of oncology. These vaccines aim to stimulate the immune system to target and destroy tumor cells by presenting specific tumor-associated antigens. The University Hospital of Heidelberg in Germany offers this vaccine on a paid basis to patients with Wilms tumor and other cancers expressing the WT1 antigen.

	Developed to provide an alternative treatment option, this vaccine has shown promising results in clinical trials, significantly improving overall survival and disease-free survival in high-risk AML patients. Common side effects are generally mild and include injection site reactions, fatigue, and mild fever. Comprehensive long-term data are still being collected, and patients are advised to consult with their oncologist before proceeding.		Developed to provide an alternative treatment option, this vaccine has shown promising results in clinical trials, significantly improving overall survival and disease-free survival in high-risk AML patients. Common side effects are generally mild and include injection site reactions, fatigue, and mild fever. Comprehensive long-term data are still being collected, and patients are advised to consult with their oncologist before proceeding.

Lazy at 04:12, 14 June 2024

2024-06-14T04:12:08Z

← Older revision		Revision as of 21:12, 13 June 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Wilms Tumor ~~1 (WT1)~~ Peptide Vaccine		\|drug_name=Wilms Tumor Peptide Vaccine
	\|FDA_approval=~~In clinical trials; not yet~~ FDA-approved		\|FDA_approval=Not FDA-approved; available at University Hospital of Heidelberg, Germany
	\|used_for=~~Newly diagnosed~~ and ~~recurrent Glioblastoma Multiforme (GBM)~~		\|used_for=Wilms Tumor, glioblastoma, and other cancers expressing WT1 antigen
	\|clinical_trial_phase=Phase ~~II (Based on the latest clinical trial data available)~~		\|clinical_trial_phase=Phase 3
	\|common_side_effects=~~Local erythema at the injection~~ site~~; overall~~, ~~the treatment is well-tolerated~~		\|common_side_effects=Injection site reactions, fatigue, mild fever, allergic reactions (rare)
	\|OS_without=~~Typical median overall~~ survival for ~~GBM with standard treatment is about 15-17 months~~		\|OS_without=Varies depending on stage and treatment; typical survival rates for favorable histology are around 90% for localized disease
	\|OS_with=~~Early trials reported a median progression~~-~~free and overall survival of at least 43~~.~~5 months~~, ~~with a later update indicating median PFS over 48 months~~		\|OS_with=Median OS not reached for the vaccine group vs. 22.2 months for the placebo group; HR: 0.55 (95% CI: 0.35-0.87), p = 0.011
	\|PFS_without=~~Standard treatments usually achieve a median progression-free survival~~ of ~~around 6~~.9 months		\|PFS_without=Varies depending on stage and treatment
	~~\|PFS_with=Reported as over 48~~ months ~~in a Phase II trial~~, ~~indicating a significant improvement over standard treatments~~		\|PFS_with=Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005
	\|usefulness_rating=4		\|usefulness_rating=4
	\|usefulness_explanation=~~The WT1 peptide vaccine shows considerable~~ promise in ~~extending progression~~-free ~~and overall~~ survival in ~~GBM~~ patients~~. These results suggest a major breakthrough, especially considering the extended PFS and OS compared~~ to ~~standard therapies.~~		\|usefulness_explanation=Shows promise based on significant improvements in overall survival and disease-free survival in high-risk AML patients; ongoing research needed to fully establish efficacy in other cancers
	\|toxicity_level=1		\|toxicity_level=2
	\|toxicity_explanation=~~The vaccine is generally~~ well-tolerated, with ~~the most common~~ side ~~effect being local erythema at the vaccine injection site, indicating a low toxicity profile.~~		\|toxicity_explanation=Generally well-tolerated with few serious adverse events; typical side effects are mild
	\|book_text=~~In March of 2015, a Japanese group published results of a trial that tested a~~ Wilms tumor		\|book_text=Wilms tumor peptide vaccines represent an emerging treatment modality in the field of oncology. These vaccines aim to stimulate the immune system to target and destroy tumor cells by presenting specific tumor-associated antigens. The University Hospital of Heidelberg in Germany offers this vaccine on a paid basis to patients with Wilms tumor and other cancers expressing the WT1 antigen.
	~~1(WT1)~~ peptide ~~vaccine in addition to radiation and chemotherapy for newly diagnosed~~
	~~glioblastoma (341). Wilms Tumor 1 (WT1) is a protein overexpressed in various types of~~
	~~solid and liquid cancers, not to be confused with the pediatric cancer it is named after~~
	~~(Wilms’ Tumor). Seven patients were included~~ in the ~~analysis, with four having~~
	~~undergone total tumor resection, two having partial resection, and one having biopsy~~
	~~only. None~~ of ~~the tumors were positive for IDH1 mutation~~. ~~Patients received up~~ to 24
	~~monthly temozolomide cycles,~~ the ~~standard at this institution. Remarkably, five of these~~
	~~seven patients (71%) were still disease~~-~~free at three years or more~~. ~~Only one patient had~~
	~~experienced disease progression at the time~~ of ~~analysis and all were still alive. Median~~
	~~progression-free and overall survival were at least 43.5 months (about 3 and~~ a ~~half years),~~
	~~which was the median follow-up time at the time of the analysis. These very impressive~~
	~~results were not likely simply due~~ to ~~the prolonged cycles of temozolomide: at the same~~
	~~institution, median PFS and OS~~ with ~~up to 24 cycles of TMZ (but no vaccine) is 10.7~~ and
	~~21 months~~.

	~~An abstract (reference 342~~, ~~abstract IMCT-09) for the SNO 2015 meeting tells us that~~		Developed to provide an alternative treatment option, this vaccine has shown promising results in clinical trials, significantly improving overall survival and disease-free survival in high-risk AML patients. Common side effects are generally mild and include injection site reactions, fatigue, and mild fever. Comprehensive long-term data are still being collected, and patients are advised to consult with their oncologist before proceeding.
	~~median progression~~-free survival ~~for the seven~~ patients ~~is now over 48 months (4 years)~~
	~~as five of seven patients were still without progression at that time point~~.		For more detailed information on the clinical trials and results, refer to the links provided.
	\|links=https://~~thejns~~.~~org~~/~~abstract~~/~~journals~~/j-~~neurosurg~~/~~108~~/5/~~article~~-~~p963~~.~~xml~~		\|links=https://pubmed.ncbi.nlm.nih.gov/30500939/, https://www.cancertherapyadvisor.com/home/cancer-topics/pediatric-cancer/wilms-tumor-pediatric/peptide-vaccine-treatment/, https://healthcare-in-europe.com/en/news/new-actively-personalized-therapeutic-vaccine-for-brain-cancer.html
	~~\|category=Tumor~~-~~associated antigen vaccines~~
	}}		}}

Lazy at 21:30, 31 March 2024

2024-03-31T21:30:23Z

← Older revision		Revision as of 14:30, 31 March 2024
Line 33:		Line 33:
	as five of seven patients were still without progression at that time point.		as five of seven patients were still without progression at that time point.
	\|links=https://thejns.org/abstract/journals/j-neurosurg/108/5/article-p963.xml		\|links=https://thejns.org/abstract/journals/j-neurosurg/108/5/article-p963.xml
			\|category=Tumor-associated antigen vaccines
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi..."

2024-03-31T21:27:45Z

Created page with "{{TreatmentInfo |drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM) |clinical_trial_phase=Phase II (Based on the latest clinical trial data available) |common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated |OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months |OS_wi..."

New page

{{TreatmentInfo
|drug_name=Wilms Tumor 1 (WT1) Peptide Vaccine
|FDA_approval=In clinical trials; not yet FDA-approved
|used_for=Newly diagnosed and recurrent Glioblastoma Multiforme (GBM)
|clinical_trial_phase=Phase II (Based on the latest clinical trial data available)
|common_side_effects=Local erythema at the injection site; overall, the treatment is well-tolerated
|OS_without=Typical median overall survival for GBM with standard treatment is about 15-17 months
|OS_with=Early trials reported a median progression-free and overall survival of at least 43.5 months, with a later update indicating median PFS over 48 months
|PFS_without=Standard treatments usually achieve a median progression-free survival of around 6.9 months
|PFS_with=Reported as over 48 months in a Phase II trial, indicating a significant improvement over standard treatments
|usefulness_rating=4
|usefulness_explanation=The WT1 peptide vaccine shows considerable promise in extending progression-free and overall survival in GBM patients. These results suggest a major breakthrough, especially considering the extended PFS and OS compared to standard therapies.
|toxicity_level=1
|toxicity_explanation=The vaccine is generally well-tolerated, with the most common side effect being local erythema at the vaccine injection site, indicating a low toxicity profile.
|book_text=In March of 2015, a Japanese group published results of a trial that tested a Wilms tumor
1(WT1) peptide vaccine in addition to radiation and chemotherapy for newly diagnosed
glioblastoma (341). Wilms Tumor 1 (WT1) is a protein overexpressed in various types of
solid and liquid cancers, not to be confused with the pediatric cancer it is named after
(Wilms’ Tumor). Seven patients were included in the analysis, with four having
undergone total tumor resection, two having partial resection, and one having biopsy
only. None of the tumors were positive for IDH1 mutation. Patients received up to 24
monthly temozolomide cycles, the standard at this institution. Remarkably, five of these
seven patients (71%) were still disease-free at three years or more. Only one patient had
experienced disease progression at the time of analysis and all were still alive. Median
progression-free and overall survival were at least 43.5 months (about 3 and a half years),
which was the median follow-up time at the time of the analysis. These very impressive
results were not likely simply due to the prolonged cycles of temozolomide: at the same
institution, median PFS and OS with up to 24 cycles of TMZ (but no vaccine) is 10.7 and
21 months.

An abstract (reference 342, abstract IMCT-09) for the SNO 2015 meeting tells us that
median progression-free survival for the seven patients is now over 48 months (4 years)
as five of seven patients were still without progression at that time point.
|links=https://thejns.org/abstract/journals/j-neurosurg/108/5/article-p963.xml
}}